The Clinical Guidelines Program is a longstanding, collaborative effort of the New York State Department of Health (NYSDOH) AIDS Institute (AI), Office of the Medical Director (OMD), and the Johns Hopkins University (JHU) School of Medicine, Division of Infectious Diseases.
Mission: To develop and disseminate practical, evidence-based clinical guidelines that promote quality medical care for people in New York who are living with and/or are at risk of acquiring HIV, HCV, STIs and substance use.
Expert committees: AIDS Institute clinical guidelines are developed by committees of expert New York State clinicians. Committee members collaborate to survey and evaluate peer-reviewed literature, write and assess clinical recommendations, and update existing guidelines or create new guidelines as necessary to ensure that recommendations reflect current best practices. All new and revised guidelines undergo peer and consumer review.
Evidence-based recommendations: Committee members apply their expertise and experience in evaluating factors that determine treatment decisions, including potential benefits and outcomes, risks, and burdens to the patient; patient views, values, and preferences; feasibility and tolerability; and the quality of evidence supporting a treatment recommendation. All recommendations are assigned ratings based on the strength and quality of the supporting evidence.
Audience: AIDS Institute clinical care guidelines are produced and disseminated to clinicians in New York who provide prevention services and medical care to people who are living with or at risk of acquiring HIV, HCV, STIs and substance use.
Stay Up-To-Date with the Clinical Guidelines Program: Subscribe to Topics, Trends & Updates to receive an email announcement when new guidelines or updates to guidelines are published, along with highlights from hot topics and events, and trends in guideline use. Subscribe now
Let Us Know What You Think: Complete our brief survey to give feedback on the guidelines and the website. Complete the survey now
- Three New Tables Added to the Drug-Drug Interactions Resource (11/25/19)
- Guideline Update: New Monitoring Intervals for CD4 Cell Count (11/22/19)
- New Guideline: PrEP to Prevent HIV and Promote Sexual Health (10/14/19)
- Topics, Trends & Updates (10/10/19)
- New Guideline: Laboratory Monitoring for Adverse Effects of ART (9/10/19)
- New Guideline: Treatment of Opioid Use Disorder (8/29/19)
- New Guideline: Harm Reduction Approach to Treatment of All Substance Use Disorders (8/29/19)
- Pocket Guide to Treatment of Opioid Use Disorder and Harm Reduction (9/3/19)
- Updates to the Talaromycosis Section of the DHHS Adult and Adolescent Opportunistic Infections Guidelines (11/21/19)
- AETC NCRC Updates (11/20/19)
- Updates to the Vaccine-Preventable Diseases Section of the DHHS Pediatric Opportunistic Infections Guidelines (10/25/19)
- AIDSinfo Releases New HIV and Heart Disease Fact Sheet (10/24/19)
- Updates to Several Tables in the DHHS Adult and Adolescent Opportunistic Infections Guidelines (10/22/19)
Final Results of the PARTNER 2 Study Confirm Undetectable = Untransmittable (U=U): Dr. Alison Rodger presented the final results of the PARTNER2 study at the 22nd International AIDS Conference in Amsterdam in July 2018. The findings of the study . . . Read more
Relative Contributions of Traditional Modifiable Risk Factors to Morbidity Among People with HIV: Compared with people who do not have HIV, people with HIV, even those with well-controlled disease, have an elevated risk of MI, ESLD, ESRD, and NADCs . . . Read more
- 1/28/20: ORN: Medications for Opioid Use Disorder in Correctional Settings (Providence, RI)
- 3/08/20: CROI 2020 (Boston, MA)
- 5/11/20: SYNChronicity (SYNC 2020) (Washington, DC)
- 7/06/20: AIDS 2020 (San Francisco and Oakland, CA)
- 8/09/20: HRSA: 2020 Ryan White HIV/AIDS Program (RWHAP) Clinical Conference (Washington, DC)